Last reviewed 2026-05-19 · How we verify

Sparcin (SPARFLOXACIN)

FDA-approved approved Small molecule Under review Quality 10/100

Sparcin (generic name: SPARFLOXACIN) is a High Risk QT Prolonging Agents drug. It is currently FDA-approved (first approved 1996) for Acute Moraxella catarrhalis bronchitis, Acute bacterial bronchitis, Bacterial infection due to Klebsiella pneumoniae.

Sparcin is a small molecule inhibitor of the molecular target Topoisomerase IV. It belongs to the drug class of inhibitors and works by inhibiting Topoisomerase IV.

At a glance

Generic name	SPARFLOXACIN
Drug class	High Risk QT Prolonging Agents
Target	Potassium voltage-gated channel subfamily H member 2
Modality	Small molecule
Therapeutic area	Infectious Disease
Phase	FDA-approved
First approval	1996

Approved indications

Acute Moraxella catarrhalis bronchitis
Acute bacterial bronchitis
Bacterial infection due to Klebsiella pneumoniae
Chlamydia Pneumoniae Bronchitis
Chlamydial pneumonia
Enterobacter Cloacae Bronchitis
Haemophilus Influenzae Bronchitis
Haemophilus Parainfluenzae Bronchitis
Haemophilus Parainfluenzae Pneumonia
Haemophilus influenzae pneumonia
Moraxella Catarrhalis Pneumonia
Pneumonia
Pneumonia due to Mycoplasma pneumoniae
Pneumonia due to Streptococcus
Staphylococcus Aureus Bronchitis
Streptococcus Pneumoniae Bronchitis

Common side effects

No common side effects on file.

Drug interactions

High Risk QT Prolonging Agents
sucralfate
ziprasidone

Key clinical trials

Patients Response to Early Switch To Oral:Osteomyelitis Study (EARLY_PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
FDA label	Mechanism, indications, dosing, boxed warnings, drug interactions
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Sparcin CI brief — competitive landscape report
Sparcin updates RSS · CI watch RSS

Frequently asked questions about Sparcin

What is Sparcin?

Sparcin (SPARFLOXACIN) is a High Risk QT Prolonging Agents drug, indicated for Acute Moraxella catarrhalis bronchitis, Acute bacterial bronchitis, Bacterial infection due to Klebsiella pneumoniae.

What is Sparcin used for?

Sparcin is indicated for Acute Moraxella catarrhalis bronchitis, Acute bacterial bronchitis, Bacterial infection due to Klebsiella pneumoniae, Chlamydia Pneumoniae Bronchitis, Chlamydial pneumonia.

What is the generic name of Sparcin?

SPARFLOXACIN is the generic (nonproprietary) name of Sparcin.

What drug class is Sparcin in?

Sparcin belongs to the High Risk QT Prolonging Agents class. See all High Risk QT Prolonging Agents drugs at /class/high-risk-qt-prolonging-agents.

When was Sparcin approved?

Sparcin was first approved on 1996.

What development phase is Sparcin in?

Sparcin is FDA-approved (marketed).

What does Sparcin target?

Sparcin targets Potassium voltage-gated channel subfamily H member 2 and is a High Risk QT Prolonging Agents.

Drug class: All High Risk QT Prolonging Agents drugs
Target: All drugs targeting Potassium voltage-gated channel subfamily H member 2
Therapeutic area: All drugs in Infectious Disease
Indication: Drugs for Acute Moraxella catarrhalis bronchitis
Indication: Drugs for Acute bacterial bronchitis
Indication: Drugs for Bacterial infection due to Klebsiella pneumoniae

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing